Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
The Netherlands Cancer Institute
M.D. Anderson Cancer Center
University of Chicago
AstraZeneca
Neonc Technologies, Inc.
Bristol-Myers Squibb